An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma-Reference-Cited by-同舟云学术

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

Published:2018-09-05 Issue:2 Volume:184 Page:215-222
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Andorsky David J.¹^ORCID,Kolibaba Kathryn S.²,Assouline Sarit³,Forero‐Torres Andres⁴,Jones Vicky⁵,Klein Leonard M.⁶,Patel‐Donnelly Dipti⁷,Smith Mitchell⁸^ORCID,Ye Wei⁹,Shi Wen⁹,Yasenchak Christopher A.¹⁰,Sharman Jeff P.¹⁰

Affiliation:

1. Rocky Mountain Cancer Centers/The US Oncology Network Boulder COUSA

2. Compass Oncology/The US Oncology Network Vancouver WA USA

3. Gerald Bronfman Centre McGill University Montreal QC Canada

4. University of Alabama at Birmingham School of Medicine Birmingham ALUSA

5. North Star Lodge Cancer Center Yakima WAUSA

6. Illinois Cancer Specialists/The US Oncology Network Niles ILUSA

7. Virginia Cancer Specialists/The US Oncology Network Fairfax VAUSA

8. School of Medicine & Health Sciences The George Washington University Washington DCUSA

9. Gilead Sciences, Inc. Foster City CA USA

10. Willamette Valley Cancer Institute and Research Center/The US Oncology Network Eugene OR USA

Funder

Gilead Sciences

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15552

Reference25 articles.

1. NOVEL DRUGS IN FOLLICULAR LYMPHOMA

2. The combination of entospletinib and vincristine demonstrates synergistic activity in a broad panel of hematological cancer cell lines and anti‐tumor efficacy in a DLBCL xenograft model;Axelrod M.J.;Blood,2015

3. BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199

4. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

5. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline;British Journal of Haematology;2023-11-13

2. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects;Critical Reviews in Oncology/Hematology;2023-10

3. Role of Tyrosine Kinases and their Inhibitors in Cancer Therapy: A Comprehensive Review;Current Medicinal Chemistry;2023-04

4. Indazole as a privileged scaffold in drug discovery;Privileged Scaffolds in Drug Discovery;2023

5. A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia;Haematologica;2022-10-13